Symptomatic Hyperventilation in Individuals Living With Stroke
Impact of Symptomatic Hyperventilation on Respiratory Parameters and Functional Capacity Among Individuals Living With Stroke: A Comparative Study
This study will investigate the effects of hyperventilation syndrome on respiratory muscle strength, respiratory muscle endurance, pulmonary functions, and functional capacity in individuals living with stroke, and in this context, stroke patients with and without hyperventilation syndrome based on Nijmegen Questionnaire scores will be compared to evaluate the relationship between symptom burden and respiratory parameters.
研究概览
地位
研究类型
注册 (估计的)
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
The study population will comprise adult individuals diagnosed with stroke (ischaemic or haemorrhagic) who are in the post-stroke period. Participants will be recruited and screened based on the Nijmegen Questionnaire score to form two distinct cohorts: individuals presenting with symptomatic hyperventilation syndrome and individuals without hyperventilation syndrome.
描述
Inclusion Criteria:
- Individuals who will be diagnosed with a confirmed first-ever or recurrent stroke (ischaemic or haemorrhagic) verified by neuroimaging (CT or MRI).
- Individuals who will be in the chronic or subacute post-stroke period (medically stable following stroke onset).
- Individuals aged 18 years and older.
- Individuals who will be classified into either the hyperventilation syndrome group based on a Nijmegen Questionnaire score of ≥23 or the control group based on a score of <23.
- Individuals who will be able to comprehend instructions and cooperate adequately with pulmonary function tests, respiratory muscle testing, and physical performance assessments.
- Individuals who will provide written informed consent to participate in the study.
Exclusion Criteria:
- Individuals who will present with severe cognitive impairment, aphasia, or psychiatric disorders that will prevent reliable completion of questionnaires (such as the Nijmegen Questionnaire) or cooperation with test procedures.
- Individuals who will have pre-existing primary chronic obstructive pulmonary disease (COPD), asthma, restrictive thoracic diseases, or other major pre-existing pulmonary pathologies that will confound pulmonary function test results.
- Individuals who will have unstable cardiovascular conditions (e.g., recent myocardial infarction within the past 3-6 months, unstable angina pectoris, uncontrolled malignant arrhythmias, or uncontrolled severe hypertension) that will pose a risk during physical testing (such as the six-minute walk test).
- Individuals who will have severe orthopedic, musculoskeletal, or lower extremity peripheral disorders unrelated to stroke that will independently limit functional capacity and walking distance (6MWD).
- Individuals who will have active respiratory tract infections or acute pulmonary illnesses at the time of evaluation. Individuals who will be participating in an active pulmonary rehabilitation program or receiving respiratory muscle training concurrently.
学习计划
研究是如何设计的?
设计细节
- 观测模型:OTHER
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Hyperventilation Syndrome Group
|
Both groups will undergo comprehensive evaluations including pulmonary function tests (FEV1, FVC, PEF), respiratory muscle strength (PImax, PEmax), respiratory muscle endurance tests, the Nijmegen Questionnaire, and the six-minute walk test (6MWT) to assess functional capacity. |
|
Without Hyperventilation Syndrome Group
|
Both groups will undergo comprehensive evaluations including pulmonary function tests (FEV1, FVC, PEF), respiratory muscle strength (PImax, PEmax), respiratory muscle endurance tests, the Nijmegen Questionnaire, and the six-minute walk test (6MWT) to assess functional capacity. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Forced Expiratory Volume in One Second (FEV1 % predicted)
大体时间:Measured at baseline/assessment
|
FEV1 percent predicted values will be measured to evaluate and compare pulmonary function between the hyperventilation syndrome group and the control group. |
Measured at baseline/assessment
|
|
Maximal inspiratory pressure (PImax)
大体时间:Measured at baseline/assessment.
|
Maximal inspiratory pressure will be assessed to determine respiratory muscle strength. |
Measured at baseline/assessment.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Maximal expiratory pressure (PEmax)
大体时间:Measured at baseline/assessment.
|
Maximal expiratory pressure will be assessed to determine respiratory muscle strength. |
Measured at baseline/assessment.
|
|
Respiratory Muscle Endurance Score
大体时间:Measured at baseline/assessment.
|
Respiratory muscle endurance scores will be recorded to evaluate breathing endurance between groups. |
Measured at baseline/assessment.
|
|
Forced Vital Capacity (FVC)
大体时间:Measured at baseline/assessment.
|
FVC percentage value will be analyzed to assess restrictive patterns and flow rates. |
Measured at baseline/assessment.
|
|
Peak Expiratory Flow (PEF)
大体时间:Measured at baseline/assessment.
|
PEF value will be analyzed to assess restrictive patterns and flow rates. |
Measured at baseline/assessment.
|
|
Six-Minute Walk Distance (6MWD)
大体时间:Measured at baseline/assessment.
|
The six-minute walk test will be performed to measure functional capacity distance in meters. |
Measured at baseline/assessment.
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.